A Study of a Single Dose of ALXN1210 in Healthy Participants

Study Identifier:
ALXN1210-HV-101
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Other
Study Drug
  • Drug: ALXN1210
  • Drug: Placebo
Date
Aug 2014 - Mar 2015
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 25 - 55 Years
Requirements Information
Sex
Female & Male
Age
25 - 55 Years

Study Details

Medical Condition
  • Other
Study Drug
  • Drug: ALXN1210
  • Drug: Placebo
Date
Aug 2014 - Mar 2015
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 25 - 55 Years years
Requirements Information

Protocol Summary

This study evaluated the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single dose of ALXN1210 in healthy participants, as assessed by electrocardiograms, physical examination, vital signs, laboratory analysis, and assessment of adverse events (AEs).

Trial Locations

Location
Status
Location
Clinical Trial Site
Montréal, Canada
Status
N/A